Compare Medpace Holdings Inc (MEDP) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs NEOS S&P 500 High Income ETF — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while NEOS S&P 500 High Income ETF trades at $54.09 (market cap $12.50B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 3,058,962). Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and NEOS S&P 500 High Income ETF for 58 Days on average.
| MEDP | SPYI | |
|---|---|---|
Market Cap | $16.82B | $12.50B |
Volume | 223,093 | 3,058,962 |
Sector | Health | Income / Options Overlay |
52-Week High | $630.19 | $54.42 |
52-Week Low | $393.42 | $47.98 |
Typical Hold Time | 14 Days | 58 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
SPYI trades at $54.09 with a slight 0.15% daily gain, showing modest upward momentum amid bullish technical signals. The ETF maintains a strong income focus with recent monthly dividends around $0.53-0.54, though key valuation metrics remain unavailable. Technical analysis indicates bullish moving averages but neutral oscillators, with RSI-6 suggesting potential overbought conditions at 72.22.
SPYI offers high-income generation through covered call strategies but faces principal erosion risks as highlighted in recent analysis. The ETF's 12% yield attracts retirement investors, though coverage warns of potential capital depletion with systematic withdrawals. Market sentiment remains mixed between income appeal and long-term growth concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
